Analysts expect the biosimilar segment alone to reach $171.8 billion by 2033, growing from $22.6 billion in 2024 at roughly 25% CAGR https://www.einpresswire.com/article/833505102/biosimilars-and-biologics-market-growth-driven-by-patent-expiries-innovation-datam-intelligence